Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

BACKGROUND: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19). METHODS: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Baadani, Abeer, Eltayeb, Nazik, Alsufyani, Eid, Albahrani, Salma, Basheri, Shareefah, Albayat, Hawra, Batubara, Enas, Ballool, Sulafa, Al Assiri, Ayed, Faqihi, Fahad, Musa, Ali B., Robert, Asirvatham A., Alsherbeeni, Nisreen, Elzein, Fatehi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166045/
https://www.ncbi.nlm.nih.gov/pubmed/34153727
http://dx.doi.org/10.1016/j.jiph.2021.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166045/
https://www.ncbi.nlm.nih.gov/pubmed/34153727
http://dx.doi.org/10.1016/j.jiph.2021.05.015

Ejemplares similares